References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

nid-1567

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Опыт применения сертикана − нового ингибитора сигнала пролиферации при трансплантации органов (Обзор литературы)

Certican - new proliferation signal inhibitor: experience in solid organ transplantation (Review)

Мойсюк

Я. Г.

Moisiuk

Y. G.

kidneytrans@mail.ru

Милосердов

И. А.

Miloserdov

I. A.

noemail@neicon.ru

НИИ трансплантологии и искусственных органов МЗ и СО РФRussian FederationКлиническая больница № 119 ФМБА МЗ и СО РФ; г. МоскваRussian Federation

2006

23062025

84336343

2025

Мойсюк Я.Г., Милосердов И.А.

Moisiuk Y.G., Miloserdov I.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/1567

В настоящее время трансплантация почки является наиболее эффективным методом заместительной почечной терапии, обеспечивая социальную реабилитацию и более высокое качество жизни пациентов по сравнению с диализной терапией [18, 34, 58]. Анализ результатов 11482 трансплантаций почки, выполненных в Канаде, показал, что 5-летняя выживаемость реципиентов выросла с 84 до 91% для операций, проведенных в 1981-1985, и 1995-1998 гг. соответственно [47]. При этом 5-летняя выживаемость трансплантатов за эти периоды также увеличилась с 63 до 80%. Вместе с тем, улучшение результатов трансплантации почки сопровождается экспоненциальным увеличением числа пациентов, находящихся в “листе ожидания”, что не может быть компенсировано количеством выполняемых операций. Так, на основании современных тенденций установлено, что к 2010 году только в США в “листе ожидания” на пересадку почки будет состоять 95550 ± 5478 пациентов, тогда как количество операций остается стабильным на протяжении последних лет и не превышает 12 000-14 000 в год [59].

иммуносупрессияингибиторы сигнала пролиферациитрансплантация органов

References1

Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin. Ann Rev Immunol 1996; 14: 483.

Bohler T., Waiser J., Budder K. et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195.

Chapman T.M., Perry C.M. Everolimus. Drugs 2004; 64 (8): 861.

Cecka J.M. The OPTN/UNOS renal transplant registry. In: Cecka J.M., Terasaki P.I. (eds). Clinical Transplant 2003. Los Angeles: UCLA Tissue Typing Laboratory 2003: 1.

Cohen B., Smits J.M., Haase B. et al. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transpt 2005; 20: 34.

Dancey J.E. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14 (3): 313.

Dunn C., Croom K.F. Everolimus. A review of its use in renal and cardiac transplantation. Drugs 2006; 66 (5): 2.

Eisen H., Dorent R., Manchini D. et al. Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis. J Heart Lung Transplant 2002; 21: 55.

Hausen B., Boeke K., Berry G.J., Segarra I.T., Christians U., Morris R.E. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150.

Hausen B., Ikonen T., Briffa N. et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76.

Haussen B., Gumbert J., Bberry G.J. et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients. Transplantation 2000; 69: 488.

Hussar D.A. New drugs of 1999. J Am Pharmaceut Soc 2000; 40: 181.

Kahan B. FTY-720 in combination with RAD: a calcineurin antagonist-free maintenance immunosuppression strategy. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey: 2001: 12.5.

Kahan B., Wong.R.L., Carter C. et al. A Phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-treated renal transplant recipients. Transplantation 1999; 68: 1100.

Kahan B., Kaplan B., Lorber M.I. et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400.

Kaplan B., Tedesco-Silva H., Mendez R. et al. Noth/South American , double-blind parallel group study of the safety and efficacy of Certican (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and corticosteroids. Am J Transplant 2001; 1 (suppl 1): 475.

Kelly P., Gruber S.A., Behbod F., Kahan B.D. Sirolimus, a new potent immunosuppressive agent. Pharmacotherapy 1997; 17: 1148.

Keown P. Improving quality of life. The new target for transplantation. Transplantation 2001; 72: 67.

Kirshner G.I., Winkler M., Muller L. et al. Pharmacokinetics of SDZ RAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 2000; 50: 449.

Kovarik J.M., Hsu C.H., McMahon L., Berthier S., Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247.

Kovarik J.M., Sabia H., Rouilly M. et al. Influence of renal and hepatic impairment on everolimus pharmacokinetics: Are dose adjustments necessary? Am J Transplant 2001; 1 (Suppl. 1): 989.

Kovarik J.M., Kahan B., Kaplan B. et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69: 48.

Kovarik J.M., Kalbag J., Figueiredo J., Rouilly M., O’Bannon L.F., Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95.

Kovarik J.M., Hartmann S., Figueiredo J. et al. Rifampin (a P450 enzyme-inducer) significantly increases the clearance of everolimus: implications for coadministration. Am J Transplant 2001; 1 (Suppl. 1): 643.

Kovarik J.М. Everolimus. A proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs of Today 2004; 40 (2): 101.

Kuypers D.R. Benefit-risk assessments of sirolimus in renal transplantation. Drug Saf 2005; 28: 153.

Leone J., Vitko S., Whelchel J. et al. Excellent graft function in de novo kidney transplant recipients treated with Certican, Simulect and reduced Neoral exposure: 24 month results. Am J Transplant 2005; 5 (Suppl 11): A1010.

Levy G.A., Grant D., Paradis K., Campestrini J., Smith T., Kovarik J.M. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160.

Levy G. A one-year, multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability, and pharmacokinetics of RAD in de novo liver transplant recipients. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey: 2001: 8.2.

Li Y., Zheng X., Li X. et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387.

Li Y., Li X., Zheng X. et al. Blocking both signal I and signal II of T-cell activation prevents apoptosis of alloreactive T-cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.

Lorber M.I., Mulgaonkar S., Butt K.M. et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.

Lorber M.I., Ponticelli C., Whelchel J. et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005; 19: 145.

Matas A.J., Lawson W., McHugh L. et al. Employment patterns after successful kidney transplantation. Transplantation 1996; 61: 729.

Majevski M., Korecka M., Kossev P. et al. The immunosuppressive macrolide RAD inhibits growth of the human Epstein-Barr virus-transformed B-lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285.

Monaco A.P., Burke J.F.Jr., Ferguson R.M. et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 round table discussion. Am J Kidney Dis 1999; 33 (1): 150.

Nankivell B.J., Borrows R.J., Fung C.L. et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.

Nashan B., Curtis J., Ponticelli C. et al. Everolimus and reduced exposure cyclosporine in de novo renal-transplant recipients: a three year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.

Nashan B. The role of Certican (everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001; 33: 3215.

Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Invest Drugs 2002; 11 (12): 1845.

Neumaer H.H., Paradis K., Korn A. et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694.

Neumayer H.H., Paradis K., Korn A. et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694.

Nicholson M.L., Metcalfe M.S., White S.A. et al. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric and living donors. Kidney Int 2000; 58: 2585.

Pascual J., Cambi V., Dissegna D. et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients: 24 months analysis. Am J Transplant 2005; 5 (Suppl 11): A1010.

Pascualal J., Ioannis N.B., Campistolc J.M. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 2006; 20: 1.

Serkova N., Hausen B., Berry G.J. et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323.

Schaubel D.E., Jeffery J.R., Mao Y. et al. Trends in mortality and graft failure for renal transplant patients. CMAJ 2002; 167: 137.

Schmidbauher G., Hancock W., Wascowska B. et al. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933.

Schuuman H.J., Schuler W., Ringers J., Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998; 30: 2198.

Schuuman H.J., Cottens S., Fuchs S. et al. SDZ RAD, a new rapamycin derivative. Transplantation 1997; 64: 32.

Schuler W., Sedrani R., Cottens S. et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.

Viella-Bach M., Nuzzi P., Fang Y., Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycinassociated protein kinase activity and G1 progression. J Biol Chem 1999; 274: 4266.

Viklicky O., Zou H., Muller V., Lacha J., Szabo A., Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.

Vitko S., Margreiter R., Weimar W. et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.

Vitko S., Margreiter R., Weimar W. et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.

Vitko S., Tedesco H., Eris J. et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.

Wells A., Li X., Li Y. et al. Requirement for T-cell apoptosis of alloreactive T-cells and induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303.

Wolfe R.A., Ashby V.B., Milford E.L. et al. Comparison of mortality in all patients on dialysis, patients on dialysis waiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.

Xue J.L., Ma J.Z., Louis T.A., Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753.

Yamashita K., Hashimoto T., Kobayshi T., Nan H. et al. Effect of new immunosuppressants RAD and FTY720 on rat liver transplantation. 2001: A Transplant Odyssey. The Future Is Here. Istanbul, Turkey: 2001: FC3. 8.

The authors declare that there are no conflicts of interest present.